The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.
 
Samantha Catherine Fisch
No Relationships to Disclose
 
Elene Tsopurashvili
No Relationships to Disclose
 
Sai Sahitha Somepalle
No Relationships to Disclose
 
Mia Salans
No Relationships to Disclose
 
Harish Vasudevan
Patents, Royalties, Other Intellectual Property - Lilly
 
Amy Jo Chien
Research Funding - Amgen (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Pending Patent Application for “COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCER”
 
Melanie Majure
No Relationships to Disclose
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)
 
Ronald Balassanian
Stock and Other Ownership Interests - Cerus
Consulting or Advisory Role - Genentech
 
Lauren Boreta
No Relationships to Disclose
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Speakers' Bureau - AstraZeneca (I); Genentech (I); Gilead Sciences (I)
Research Funding - DAEHWA Pharmaceutical (Inst); Novartis (Inst); OBI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline
 
Laura Ann Huppert
Consulting or Advisory Role - AstraZeneca; Pfizer